Has Tomer Mark received payments from drug or device companies?

Yes. Drug and device makers reported $95,684 in general payments to Tomer Mark across 78 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tomer Mark did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tomer Mark come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tomer Mark

Hematology & Oncology · Aurora, CONPI 1891981346

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (36.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Amgen at 36.1% of the total. Reporting peaked in 2019 at $64,380 and has fallen 98.8% since, to $746 in 2022.

$95,684in general payments, 2019–2025

Across 78 payments — averaging $1226.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$35K
Bristol Myers Squibb$24K
Karyopharm Therapeutics Inc.$18K
Adaptive Biotechnologies Corporation$6K
Sanofi$5K
Genentech, Inc.$3K
plus $5K from 4 others

$1,254,198in research payments, 2019–2025

Across 133 payments — averaging $9430.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bristol Myers Squibb$685K
Janssen Research & Development, LLC$506K
E.r. Squibb & Sons, L.L.C.$26K
Amgen$19K
Adaptive Biotechnologies Corporation$16K
Karyopharm Therapeutics Inc.$3K

What the payments were for

Consulting fees$25,69927%
Speaking & faculty fees$33,80035%
Travel & lodging$34,86036%
Food & beverage$1,3031%
Education$220%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	27	$34,571
Bristol Myers Squibb	16	$24,352
Karyopharm Therapeutics Inc.	14	$17,977
Adaptive Biotechnologies Corporation	2	$5,880
Sanofi	6	$4,915
Genentech, Inc.	5	$2,901
Takeda Pharmaceuticals U.S.A., Inc.	3	$2,827
GSK	2	$2,194
Johnson & Johnson	2	$49
Beigene USA, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Kyprolis$33,782
Revlimid$22,171
XPOVIO$17,899
clonoSEQ$5,880
CD38$4,044
Venclexta$2,840
NINLARO$2,805
BLENREP$2,175
SARCLISA$729
Pomalyst$476

How this compares

$95,684 in reported general payments places this provider in the 85th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado →

Other hematology & oncology in Aurora

John BurkeAurora$321K
Douglas ReznickAurora$294K
Daniel PollyeaAurora$274K
Sami DiabAurora$134K
Manali KamdarAurora$129K
Bradley HaverkosAurora$120K
Sujatha NallapareddyAurora$112K
Ara MetjianAurora$89K
Ryan WeightAurora$65K
Breelyn WilkyAurora$46K

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →